Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Franci, Christian ^a   Zhou, Jenny ^a   Jiang, Zhaoshi ^a   Modrusan, Zora ^a   Good, Zinaida ^a   Jackson, Erica ^a   Kouros Mehr, Hosein ^a,b  

^a GENENTECH INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; JANUS KINASE; NOTCH RECEPTOR; STAT1 PROTEIN;

ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER RECURRENCE; CARCINOMA; CELL POPULATION; DISSEMINATED CANCER; DNA DAMAGE; FEMALE; HYPERPLASIA; LUNG METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MINIMAL RESIDUAL DISEASE; MODIFIER GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM; STAT TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874782595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058183     Document Type: Article

References (73)

1. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
2. Weigelt B, Hu Z, He X, Livasy C, Carey LA, et al. (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155-9158.
3. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
4. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
5. Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, et al. (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371: 29-40.
6. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, et al. (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13: 688-695.
7. Slade MJ, Coombes RC, (2007) The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 4: 30-41.
8. Aguirre-Ghiso JA, (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
9. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, et al. (2012) Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 118: 342-348.
10. Goss PE, Chambers AF, (2010) Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10: 871-877.
11. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
12. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, et al. (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8: 227-239.
13. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, et al. (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360: 683-689.
14. Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, et al. (2008) Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27: 2148-2158.
15. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, et al. (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 100: 15901-15905.
16. Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
17. Ramaswamy S, Ross KN, Lander ES, Golub TR, (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
18. Weigelt B, Peterse JL, van 't Veer LJ, (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602.
19. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
20. Naumov GN, MacDonald IC, Chambers AF, Groom AC, (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11: 271-276.
21. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
22. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
23. Fidler IJ, Kripke ML, (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895.
24. Montel V, Huang TY, Mose E, Pestonjamasp K, Tarin D, (2005) Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 166: 1565-1579.
25. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
26. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, et al. (2012) RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487: 510-513.
27. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, et al. (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126.
28. Guy CT, Cardiff RD, Muller WJ, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
29. Rodriguez-Viciana P, Collins C, Fried M, (2006) Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci U S A 103: 19290-19295.
30. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
31. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, et al. (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152.
32. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, et al. (2007) A comparison of background correction methods for two-colour microarrays. Bioinformatics 23: 2700-2707.
33. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, et al. (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17: 1205-1212.
34. Sheen-Chen SM, Huang CC, Tang RP, Yang CH, Chou FF, et al. (2007) Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray. Anticancer Res 27: 2481-2486.
35. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, et al. (2004) STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 101: 1714-1719.
36. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, et al. (2009) STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 4: e5821.
37. Townsend PA, Cragg MS, Davidson SM, McCormick J, Barry S, et al. (2005) STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci 118: 1629-1639.
38. Watson CJ, Miller WR, (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844.
39. Clevenger CV, (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165: 1449-1460.
40. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
41. Sorlie T, (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40: 2667-2675.
42. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, et al. (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7: 127.
43. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
44. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
45. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
46. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
47. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, et al. (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735.
48. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, et al. (2007) Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 67: 3845-3852.
49. Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV, (2006) GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol 57: 25-33.
50. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 105: 18490-18495.
51. Fryknas M, Dhar S, Oberg F, Rickardson L, Rydaker M, et al. (2007) STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer 120: 189-195.
52. Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, et al. (2005) Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 93: 483-492.
53. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, et al. (2006) Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25: 6113-6122.
54. Roberts D, Schick J, Conway S, Biade S, Laub PB, et al. (2005) Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149-1158.
55. Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP, (2011) A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells. PLoS One 6: e19861.
56. Gilbert LA, Hemann MT, (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143: 355-366.
57. Zhang X, Xiao W, Wang L, Tian Z, Zhang J, (2011) Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One 6: e20965.
58. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, et al. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618.
59. Zhang GJ, Adachi I, (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19: 1427-1432.
60. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, et al. (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103: 642-646.
61. Ancrile B, Lim KH, Counter CM, (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719.
62. Garcia R, Bowman TL, Niu G, Yu H, Minton S, et al. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513.
63. Knupfer H, Preiss R, (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102: 129-135.
64. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17: 6083-6096.
65. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
66. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, et al. (2012) Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 109: E2939-2948.
67. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, et al. (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
68. Greer EL, Shi Y, (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13: 343-357.
69. Albert M, Helin K, (2010) Histone methyltransferases in cancer. Semin Cell Dev Biol 21: 209-220.
70. Popovic R, Licht JD, (2012) Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2: 405-413.
71. van Attikum H, Gasser SM, (2009) Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol 19: 207-217.
72. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, et al. (2012) The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene.
73. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, et al. (2010) H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 70: 7830-7840.